Wu Capital has led a series A round for Korro Bio, whose RNA editing technology was developed at UChicago-affiliated Marine Biological Laboratory.

Korro Bio, a US-based RNA therapy developer based on Marine Biological Laboratory research, raised $91.5m yesterday in a series A round led by Wu Capital.

Alexandria Venture Investments, the strategic investment division of life sciences real estate investment trust Alexandria Real Estate Equities, backed the round alongside Atlas Venture, New Enterprise Associates, Qiming Venture Partners USA, Surveyor Capital, Cormorant Asset Management and MP Healthcare Venture Management.

Korro Bio is developing drugs using an RNA editing platform called Opera that leverages…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?